Treatment of Advanced Stage Epithelial Ovarian Cancer

Key points
- A scheme for the management of patients with advanced-stage epithelial ovarian cancer is presented in Figure 118-6.
- Cytoreductive Surgery in Ovarian Cancer Patients who have advanced-stage epithelial ovarian cancer documented at initial exploratory laparotomy should undergo cytoreductive surgery to remove as much of the tumor and its metastases as possible in order to facilitate the effectiveness of subsequent therapies.
- The principal goal of cytoreductive surgery is to remove all of the primary cancer and, if possible, its metastases.
- The ability of cytoreductive surgery to influence survival is limited by the size, extent, and location of metastases prior to cytoreduction, and presumably by the presence of drug-resistant cells.
A scheme for the management of patients with advanced-stage epithelial ovarian cancer is presented in Figure 118-6. The components of this approach are discussed below.
Cytoreductive Surgery in Ovarian Cancer
Patients who have advanced-stage epithelial ovarian cancer documented at initial exploratory laparotomy should undergo cytoreductive surgery to remove as much of the tumor and its metastases as possible in order to facilitate the effectiveness of subsequent therapies. The operation usually includes the performance of a total abdominal hysterectomy and bilateral salpingo-oophorectomy, a complete omentectomy, and resection of metastatic lesions on the peritoneal surfaces or from the intestines. In addition, the pelvic tumor may directly involve the rectosigmoid colon, the terminal ileum, and the cecum. In some patients, most or all of their disease is confined to the pelvic viscera and the omentum, so that removal of these organs results in the extirpation of all gross tumor, a situation that is associated with a reasonable chance of complete response.
The rationale for cytoreductive surgery relates to three general theoretical considerations: (1) potential physiologic benefits from excising the tumor; (2) improved tumor perfusion and increased growth fraction, that may increase the likelihood of a response to chemotherapy or radiation therapy; and (3) enhanced immunologic competence of the patient.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMotor protein may offer promise in ovarian cancer treatment
A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers. Among U.S.…
27 April 2011
NewsBNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer
Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of a special carrier substance…
5 March 2011
NewsNew treatment to overpower drug resistance in ovarian cancer
Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.…






